Abivax is preparing a regulatory submission in the U.S. in the second half of 2026, provided an ongoing maintenance trial ...

Terns Pharmaceuticals shares jumped as much as 50% on news that cancer cell counts fell over 99% in nearly three-fourths of ...

Seventy-three pharmaceutical, biotechnology and medical device companies from mainland China filed for IPOs in Hong Kong this year, a review by BioWorld found. In the second half of 2025, 43 new ...

Discover why Terns Pharmaceuticals, Inc. stock is up 770% YTD with strong CML drug data and major upcoming milestones. Click ...

ASH's 2025 meeting ended with strong multiple myeloma data from J&J, a new treatment for a rare disorder, and strains on a ...

Saol Therapeutics received a complete response letter for its pyruvate dehydrogenase complex deficiency treatment a week ...

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

Today we discuss why comparing U.S. vaccine policy to Europe’s is a red herring, why the revolving door at the FDA between ...

Using patented purification methods and a community-first growth strategy, the Root Brands is redefining what it means to ...

Exicure’s investigational small molecule succeeded in mobilizing key blood-forming cells in almost 90% of patients in a phase ...

The company recently shook up its leadership structure as it pursues a Phase 2 study.

Cooley LLP hired three partners and a 30-person team from Dechert LLP to grow its Boston life sciences practice and support the biotech sector.